Dalbavancin in Bone and Joint Infections: A Systematic Review
Open Access
- 15 July 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 1005
Abstract
Background: Approved for acute bacterial skin and skin structure infections, dalbavancin (DBV) has gradually acquired over the years a role as an off-label treatment for several infections caused by Gram-positive bacteria even in other anatomical sites. Osteoarticular (OA) infections are one of the most difficult-to-treat infections and, since the absence of recommendations, clinicians use different and heterogenic DBV dosing schedule regimens for the off-label treatment of osteomyelitis, spondylodiscitis, and septic arthritis. Our aim is to systematically review the current literature to describe DBV administration schedules and their outcome in OA infections. Methods: According to the 2020 updated PRISMA guidelines, all peer-reviewed articles regarding the use of DBV in OA infections were included. We conducted a literature search on PubMed and Cochrane Controlled Trials. Results: A total of 23 studies and 450 patients were included, prevalently male (144/195, 73.8%) and diabetic (53/163, 32.5%). Overall, 280 (280/388, 72.2%) osteomyelitis, 79 (79/388, 20.4%) spondylodiscitis, and 29 (29/388, 7.5%) septic arthritis were considered. Staphylococcus aureus (164/243, 67.5%) was the most common pathogen isolated. A previous treatment failure (45/96, 46.9%) was the main reason for a switch to a long-acting antibiotic. Most patients were successfully cured with DBV (318/401, 79.3%). A source control was performed in most patients with a favourable outcome (80.4%), while MRSA was prevalently isolated in people with an unfavourable outcome (57%). While a higher percentage of success was found in people who received three doses of DBV 1 week apart (92.3%), a higher rate of treatment failure was recorded in cases of when the DBV cycle was composed of less than two or more than four doses (27.8%). Conclusions: DBV has shown to be effective as a treatment for OA infections. The most favourable outcome was found in patients receiving three doses of DBV and with an adequate surgical management prior to antibiotic treatment. Although a rigorous administration schedule does not exist, DBV is a viable treatment option in the management of OA infections.Keywords
This publication has 58 references indexed in Scilit:
- In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infectionsDiagnostic Microbiology and Infectious Disease, 2016
- 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in AdultsaClinical Infectious Diseases, 2015
- Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular TissueAntimicrobial Agents and Chemotherapy, 2015
- Recommendations for the treatment of osteomyelitisThe Brazilian Journal of Infectious Diseases, 2014
- Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection modelInternational Journal of Antimicrobial Agents, 2013
- Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)Diagnostic Microbiology and Infectious Disease, 2013
- Surgical Treatment of OsteomyelitisPlastic and Reconstructive Surgery, 2011
- Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic ImpairmentThe Journal of Clinical Pharmacology, 2009
- In Vivo Pharmacodynamic Activity of the Glycopeptide DalbavancinAntimicrobial Agents and Chemotherapy, 2007
- Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?International Journal of Infectious Diseases, 2005